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ABsTrACT 
We report a cohort study of survival of patients with 
lung cancer presenting to a single multidisciplinary team 
between 1997 and 2011, according to symptoms at 
presentation. The overall median survival of the 3800 
lung cases was 183 days (95% CI 171 to 195). There was 
a statistically signiicant difference in survival between 
the 12 symptom groups identiied both without and 
with adjustment for the prognostic variables of age, 
gender and histology (P<0.001). Compared with the 
cough-alone symptom group, the risks of dying or HRs 
were signiicantly higher for the groups presenting with 
breathlessness (HR 1.86, 95% CI 1.54 to 2.24, n=359), 
systemic symptoms (HR 1.91, 95% CI 1.48 to 2.45, 
n=95), weight loss (HR 2.46, 95% CI 1.90 to 3.18, 
n=106), chest pain (HR 1.96, 95% CI 1.56 to 2.45, 
n=159), cough with breathlessness (HR 1.59 95% CI 
1.28 to 1.98, n=177), neurological symptoms (HR 
3.07, 95% CI 2.45 to 3.84, n=155) and other symptom 
combinations (HR 2.05, 95% CI 1.75 to 2.40, n=1963). 
Cough may deserve particular prominence in public 
health campaigns.
InTroduCTIon
We have previously reported an attempt to 
improve the timeliness of diagnosis of lung cancer 
by raising the awareness of cough as a possible 
symptom.1 Cough was chosen because it is a 
common lung cancer symptom and does not neces-
sarily imply advanced disease. In this study we have 
investigated the extent to which the various pres-
entations of lung cancer may predict outcome.
MeThods
This was a retrospective cohort study. An original 
database was designed to identify the presenting 
symptoms elicited at the first secondary care 
contact for all cases reviewed in the Doncaster-Bas-
setlaw lung cancer multidisciplinary team (MDT) 
meeting, presenting between 1 October 1997 and 
1 March 2011. Only cases with a histological diag-
nosis of lung cancer or a clinical diagnosis based on 
the opinion of the lung MDT and with a consistent 
subsequent clinical course were included. We iden-
tified 10 groups comprising the most common 
symptomatic presentations, an asymptomatic group 
presenting with an abnormal radiograph and a 
group with rarer symptoms/symptom combinations 
(see table 1).
We preferred the date of first MDT discussion as 
the reference point from which survival was meas-
ured, as the date of diagnosis could sometimes be 
significantly delayed; this generally occurred within 
3 weeks of initial presentation and was available for 
all cases, irrespective of mode of presentation.
Statistical methods are given in online supple-
mentary appendix 1.
resulTs
The Consolidated Standards of Reporting Trials 
diagram (figure 1) describes the case selection. 
A similar average age at presentation and a male 
predominance were found in all symptom groups 
(table 1).
The overall median survival of the 3800 lung 
cases was 183 days (95% CI 171 to 195), and was 
significantly better for patients presenting with 
cough (n=226, 398 days; 95% CI 316 to 480), 
haemoptysis (n=188, 308 days; 95% CI 248 to 
368), cough and haemoptysis (n=100, 370 days; 
95% CI 300 to 440), and lower respiratory tract 
infection (n=52, 410 days; 95% CI 218 to 602). 
Survival after cough presentations was similar to 
that of the abnormal radiograph group (see table 2 
and Kaplan-Meier curves in figure 2). The differ-
ence in survival between the 12 symptom groups 
was statistically significant both without (log-rank 
P<0.001) and with adjustment for the prognostic 
variables of age, gender and histology (ie, small 
cell lung cancer (SCLC) vs non-small cell cancer 
(NSCLC)) (P<0.001).
We undertook a symptom group × SCLC inter-
action analysis because of the more aggressive 
behaviour of this tumour. The 518 cases with SCLC 
were more likely to present with other symptom 
combinations (62.9%) and were less likely to 
present with cough/haemoptysis (9.3%) or with 
an asymptomatic radiological abnormality (2.9%). 
Although the survival of the SCLC group was signif-
icantly poorer, there was no statistical evidence of 
a presenting symptom cluster by SCLC interaction 
(P=0.40), indicating that the effects of presenting 
symptoms on survival are similar across the SCLC 
and NSCLC patient groups.
dIsCussIon
There are several possible explanations for the 
far superior prognosis of symptomatic patients 
presenting with cough (either simple, associated 
with haemoptysis or with purulent sputum), with 
a median survival approximately twice as long as 
that seen after any other symptomatic presentation. 
Most obviously these symptoms were associated 
with earlier stage and consequent higher radical 
treatment rates. It is therefore possible that these 
symptoms may correspond to discovery at an earlier 
stage in the natural history of the cancer when 
patients are still amenable to curative treatment.
Other putative factors that a priori may have 
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  n 226 220 188 100 52 359 106 95 159 177 155 1963 3800
  Mean 69.4 71.4 69 68.3 70.2 73.2 72.3 72.6 68.9 71.3 68.8 69.9 70.3
  SD 9.7 9.9 9.7 10.7 10 9.2 10.2 10.5 10.1 8.8 10.9 10.2 10.1
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Gender 
  Male 133 (59) 128 (58) 137 (73) 67 (67) 26 (50) 209 (58) 67 (60) 55 (59) 97 (61) 92 (52) 91 (59) 1142 (58) 2241 (59)
  Female 93 (41) 92 (42) 51 (27) 33 (33) 26 (50) 150 (42) 42 (40) 39 (41) 62 (39) 85 (48) 64 (41) 821 (42) 1558 (41)
  Total 226 (100) 220 (100) 188 (100) 100 (100) 52 (100) 359 (100) 106 (100) 94 (100) 159 (100) 177 (100) 155 (100) 1963 (100) 3799 (100)
Lung cancer stage 
  I 50 (22) 74 (34) 39 (20) 26 (26) 13 (25) 53 (15) 19 (18) 8 (9) 14 (9) 19 (11) 6 (4) (9) 488 (13)
  II 12 (5) 8 (4) 10 (5) 5 (5) 2 (4) 17 (5) 4 (4) 2 (2) 10 (6) 8 (5) 1 (1) 51 (3) 130 (3)
  III 78 (35) 49 (22) 47 (25) 26 (26) 12 (23) 114 (32) 22 (20) 24 (26) 42 (26) 60 (34) 13 (8) 543 (28) 1030 (27)
  IV 57 (25) 48 (22) 53 (28) 28 (28) 12 (23) 89 (25) 33 (31) 32 (34) 70 (44) 52 (29) 109 (70) 735 (38) 1318 (35)
  Limited 10 (4) 10 (5) 10 (5) 5 (5) 3 (6) 14 (4) 5 (5) 4 (4) 6 (4) 13 (7) 4 (3) 107 (6) 191 (5)
  Extensive 6 (3) 3 (1) 8 (4) 4 (4) 4 (8) 17 (5) 12 (11) 24 (26) 7 (4) 10 (6) 16 (10) 163 (8) 274 (7)
  Clinical 13 (6) 28 (13) 21 (11) 6 (6) 6 (12) 55 (15) 11 (10) 0 (0) 10 (6) 15 (8) 6 (4) 195 (10) 366 (10)
  Total 226 (100) 220 (100) 188 (100) 100 (100) 52 (100) 359 (100) 106 (100) 94 (100) 159 (100) 177 (100) 155 (100) 1961 (100) 3797 (100)
Lung cancer histology 
  NSCLC-nos 64 (28) 46 (21) 60 (32) 24 (24) 12 (23) 80 (22) 24 (22) 30 (32) 66 (42) 41 (23) 29 (19) 504 (26) 980 (26)
  Adenocarcinoma 29 (13) 41 (19) 15 (8) 10 (10) 4 (8) 66 (18) 10 (9) 2 (2) 22 (14) 33 (19) 19 (12) 213 (11) 464 (12)
  BAC 4 (2) 1 (1) 2 (1) 2 (2) 0 (0) 2 (1) 0 (0) 0 (0) 0 (0) 3 (2) 0 (0) 6 (0) 20 (1)
  Squamous 73 (32) 45 (21) 60 (32) 38 (38) 12 (23) 58 (16) 23 (22) 15 (16) 28 (18) 44 (25) 11 (7) 422 (22) 829 (22)
  Other NSCLC 4 (2) 7 (3) 6 (3) 4 (4) 2 (4) 1 (0) 1 (1) 11 (12) 1 (1) 1 (1) 4 (3) 44 (2) 86 (2)
  SCLC 19 (8) 15 (7) 20 (11) 9 (9) 12 (23) 36 (10) 18 (17) 0 (0) 15 (9) 27 (15) 21 (14) 326 (17) 518 (14)
  Clinical 33 (15) 63 (29) 25 (13) 13 (13) 10 (19) 116 (32) 30 (28) 37 (39) 27 (17) 28 (16) 71 (46) 448 (23) 901 (24)
  Total 226 (100) 218 (100) 188 (100) 100 (100) 52 (100) 359 (100) 106 (100) 95 (100) 159 (100) 177 (100) 155 (100) 1963 (100) 3798 (100)
Treatment 
  Resection 47 (21) 54 (25) 43 (23) 22 (22) 9 (17) 31 (9) 10 (9) 6 (6) 11 (7) 13 (7) 4 (3) 108 (6) 358 (9)
  Rad XRT 25 (11) 22 (10) 10 (5) 5 (5) 2 (4) 14 (4) 5 (5) 2 (2) 8 (5) 5 (3) 3 (2) 91 (5) 192 (5)
  Chemo 55 (24) 42 (19) 47 (25) 29 (29) 15 (29) 52 (15) 22 (21) 14 (15) 32 (20) 54 (31) 18 (12) 475 (24) 855 (23)
  Pall XRT 45 (20) 22 (10) 51 (27) 24 (24) 6 (12) 64 (18) 12 (11) 13 (14) 53 (33) 39 (22) 53 (34) 545 (28) 927 (24)
  Multimodal 19 (8) 9 (4) 4 (2) 6 (6) 6 (12) 13 (4) 8 (8) 2 (2) 14 (9) 15 (9) 0 (0) 64 (3) 160 (4)
  BSC 29 (13) 69 (32) 29 (15) 13 (13) 11 (21) 169 (47) 41 (39) 58  (61) 40 (25) 50 (28) 71 (46) 577 (29) 1157 (31)
  Died prior 1 (0) 0 (0) 1 (1) 0 (0) 1 (2) 0 (0) 3 (3) 0 (0) 0 (0) 0 (0) 6 (4) 83 (4) 95 (3)
  Unknown 5 (2) 1 (1) 3 (1) 1 (1) 2 (4) 12 (3) 5 (5) 0 (0) 1 (1) 1 (1) 0 (0) 19 (1) 50 (1)
  Erlotinib 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 4 (1) 0 (0) 0 (0) 0 (1) 0 (0) 0 (0) 0 (0) 4 (0)
Continued








































































































































































































































































































































































































































































  Total 226 (100) 219 (100) 188 (100) 100 (100) 52 (100) 359 (100) 106 (100) 95 (100) 159 (100) 177 (100) 155 (100) 1962 (100) 3798 (100)
Performance status 
  0 74 (40) 53 (34) 48 (34) 30 (36) 13 (30) 29 (11) 21 (26) 7 (10) 48 (37) 27 (18) 15 (12) 257 (16) 623 (21)
  1 75 (41) 47 (30) 55 (38) 36 (43) 17 (40) 74 (28) 21 (26) 18 (25) 42 (33) 63 (43) 27 (21) 528 (34) 1003 (33)
  2 24 (13) 24 (15) 17 (12) 9 (11) 9 (21) 65 (24) 14 (18) 13 (18) 19 (15) 31 (21) 26 (20) 340 (22) 591 (20)
  3 6 (3) 18 (11) 20 (14) 5 (6) 2 (5) 60 (22) 16 (20) 14 (19) 18 (14) 18 (12) 22 (17) 292 (19) 491 (16)
  4 3 (3) 16 (10) 3 (2) 3 (4) 2 (5) 40 (15) 8 (10) 21 (29) 2 (2) 9 (6) 38 (30) 158 (10) 305 (10)
  Total 184 (10) 158 (100) 144 (100) 83 (100) 43 (100) 268 (100) 80 (100) 73 (100) 129 (100) 148 (100) 128 (100) 1575 (100) 3013 (100)
Other symptoms category includes gastrointestinal symptoms, hoarse voice, wheeze, facial swelling, mass, fracture, fall and stridor.
LRTI was diagnosed when clinical features strongly suggested an infective component, including sputum purulence, fever and acute constitutional symptoms.
Systemic symptoms included otherwise unexplained weight loss and lethargy. Neurological symptoms were mostly due to cerebral metastases.
Performance status score: The Eastern Cooperative Oncology Group score  runs from 0 to 5, with 0 denoting perfect health and 5 death: 0—asymptomatic (fully active, able to carry on all predisease activities without restriction); 1—symptomatic but completely ambulatory (restricted in physically 
strenuous activity but ambulatory and able to carry out work of a light or sedentary nature; for example, light housework, ofice work); 2—symptomatic, <50% in bed during the day (ambulatory and capable of all self-care but unable to carry out any work activities;  up and about more than 50% of 
waking hours); 3—symptomatic, >50% in bed, but not bedbound (capable of only limited self-care, conined to bed or chair 50% or more of waking hours); 4—bedbound (completely disabled; cannot carry on any self-care; totally conined to bed or chair); 5—death.
BAC, bronchioloalveolar carcinoma; chemo, chemotherapy; LRTI, lower respiratory tract infection; multimodal, multimodality therapy (chemotherapy and either radiotherapy or surgery); NSCLC-nos, non-small cell lung cancer, not otherwise speciied; Pall XRT, palliative radiotherapy; rad XRT, radical 
radiotherapy; BSC, best supportive care; SCLC, small cell lung cancer.
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bronchioloalveolar cell/minimally invasive adenocarcinomas, of 
which there was no excess in our study, suggesting that over-
diagnosis is unlikely to be responsible. Lead-time bias is also 
unlikely to explain our results because the survival rates out to 5 
years and beyond from diagnosis remained superior in the cases 
presenting with coughs, indicating a higher rate of cure.
We were unable to correct for comorbidity, which may have 
contributed to additional presenting symptoms such as breath-
lessness, weight loss and so on, and may have mediated some 
of the outcome differences observed. It is also possible that 
Table 2 Unadjusted and adjusted HRs for dying, from Cox proportional hazards multiple regression model, for presenting symptom groups 




95% CI for hr
P values
Adjusted* hr 95% CI for hr
P valueslower upper lower upper
Abnormal radiograph  vs cough 1.01 0.81 1.26 0.921 0.98 0.79 1.22 0.876
Haemoptysis vs cough 1.19 0.95 1.48 0.130 1.19 0.96 1.49 0.117
Cough and haemoptysis vs cough 0.96 0.73 1.26 0.755 0.98 0.74 1.29 0.874
LRTI vs cough 1.10 0.77 1.56 0.609 1.06 0.74 1.51 0.756
Breathlessness vs cough 1.86 1.54 2.24 <0.001 1.74 1.44 2.10 <0.001
Systemic symptoms vs cough 1.91 1.48 2.45 <0.001 1.74 1.35 2.24 <0.001
Weight loss vs cough 2.46 1.90 3.18 <0.001 2.36 1.82 3.06 <0.001
Chest pain vs cough 1.96 1.56 2.45 <0.001 1.99 1.59 2.49 <0.001
Cough and breathlessness vs cough 1.59 1.28 1.98 <0.001 1.52 1.23 1.90 <0.001
Neurological vs cough 3.07 2.45 3.84 <0.001 3.06 2.44 3.83 <0.001
Other symptom combinations vs cough 2.05 1.75 2.40 <0.001 2.04 1.74 2.39 <0.001
Age (years) 1.02 1.02 1.03 <0.001
Gender (female) 0.91 0.85 0.98 0.007
Histology (small cell cancer) 1.18 1.07 1.31 0.001
Unadjusted analysis, n=3800; adjusted analysis, n=3796.
An HR >1 means patients in the symptom group have a greater risk or hazard of dying than patients in the reference (cough alone) symptom group.
Other symptom combinations category includes gastrointestinal symptoms, hoarse voice, wheeze, facial swelling, mass, fracture, fall and stridor.
*Adjusted for age, gender and histology (small cell lung cancer, yes or no).
LRTI, lower respiratory tract infection.
Figure 2 Kaplan-Meier curves for overall survival (in days) for the 12 symptom groups for the 3800 lung cancer cases. LRTI, lower respiratory tract 
infection. XR, X-ray. SOB, shortness of breath
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patients presenting with a single symptom in primary care could 
have developed additional symptoms in the interval leading up 
to secondary care assessment, especially with more aggressive 
cancers.
Ades and colleagues using casecontrol methodology failed to 
show any relationship between lung cancer symptoms recorded 
in primary care and disease stage, concluding that there is little 
prospect of improving outcomes by earlier detection of sympto-
matic disease.3 4 Although our population was likely to be slightly 
later in the natural history of the condition, our findings seem to 
contradict that conclusion, at least in relation to the symptom of 
cough. This may be because our study is much more powerful, 
with theirs only including 247 patients with lung cancer.
It is probable that these results are generalisable to British 
patients presenting with lung cancer. We do not yet know for 
certain that expediting the diagnosis in patients complaining 
of isolated cough in its various forms will improve outcomes, 
but these symptoms are certainly logical choices for awareness 
campaigns.
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